Current situation of immuno-oncology development

MAO Yanyan; HUANG Yaoqing; GAO Liubin

doi:10.3981/j.issn.1000-7857.2017.11.009

PDF(1064 KB)

Science & Technology Review ›› 2017, Vol. 35 ›› Issue (13) : 61-65. DOI: 10.3981/j.issn.1000-7857.2017.11.009

Articles

Current situation of immuno-oncology development

Author information -

Shanghai Institute of Material Medical, Chinese Academy of Sciences, Shanghai 201203, China

Abstract

Cancer is the most serious threat to human health and the most attractive disease in research. With unique advantages in cancer treatment, immuno-oncology is favored by more and more research institutions and pharmaceutical companies, showing a trend of vigorous development in recent years. Due to the complexity of the immune system, cancer immunotherapy covers a variety of action mechanisms and drug forms with different development stages. Based on literature research and database retrieval, the overall situations of development stage, mechanism of action, as well as research institutions of drugs in clinical trials or in market are reported and analyzed in this paper, for depicting the general trend and direction of immunotherapies development and providing references for research and development of antitumor drugs.

Key words

anti-tumor / immuno-oncology / CAR-T cell therapy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

MAO Yanyan, HUANG Yaoqing, GAO Liubin. Current situation of immuno-oncology development[J]. Science & Technology Review, 2017, 35(13): 61-65 https://doi.org/10.3981/j.issn.1000-7857.2017.11.009

References

[1] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA: A Cancer Journal for Clinicians, 2015, 65(2): 87-108.
[2] Cheever M A, Higano C S. PROVENGE (Sipuleucel-T) in prostate can- cer: The first FDA-approved therapeutic cancer vaccine.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2011, 17(11): 3520.
[3] Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melano- ma: serious side effects and a hefty price tag may limit its use[J]. Phar- macy and Therapeutics, 2012, 37(9): 503.
[4] Hodi F S, O'day S J, McDermott D F, et al. Improved survival with ipil- imumab in patients with metastatic melanoma[J]. New England Journal of Medicine, 2010, 363(8): 711-723.
[5] Hoos A. Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations[J]. Nature Reviews Drug Discovery, 2016, 15(4): 235.
[6] Robert C. Science's Top 10 Breakthroughs of 2013[EB/OL]. [2017-01- 27], http://www.sciencemag.org/news/2013/12/sciences-top-10-break- throughs-2013-0
[7] Poole R M. Pembrolizumab: First global approval.[J]. Drugs, 2014, 74 (16): 1973-1981.
[8] Raedler L A. Opdivo (Nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma[J]. Am Health Drug Benefits, 2015, 8: 180-183.
[9] Markham A. Atezolizumab: First global approval[J]. Drugs, 2016, 76 (12): 1-6.
[10] Przepiorka D, Ko C W, Deisseroth A, et al. FDA approval: Blinatu- momab[J]. Clinical Cancer Research an Official Journal of the Ameri- can Association for Cancer Research, 2015, 21(18): 4035.
[11] Coffin R. Interview with Robert Coffin, inventor of T-VEC: The first oncolytic immunotherapy approved for the treatment of cancer[J]. Im- munotherapy, 2016, 8(2): 103.
[12] Chen D S, Mellman I. Oncology meets immunology: The cancer-immu- nity cycle[J]. Immunity, 2013, 39(1): 1.
[13] Antonia S J, Larkin J, Ascierto P A. Immuno-oncology combinations: A review of clinical experience and future prospects[J]. Clinical Can- cer Research, 2014, 20(24): 6258-6268.
[14] Finn O J. Immuno-oncology: Understanding the function and dysfunc- tion of the immune system in cancer[J]. Annals of Oncology, 2012, 23 (Suppl 8): viii6-viii9.
[15] Kintzing J R, Interrante M V F, Cochran J R. Emerging strategies for developing next-generation protein therapeutics for cancer treatment[J]. Trends in Pharmacological Sciences, 2016, 37(12): 993-1008.
[16] 刘丽丽, 毛艳艳, 高柳滨. 新靶点新技术涌现，精准治疗前景可期 ——2016 药物研发进展回眸[J]. 科技导报, 2017, 35(1): 100-106. Liu Lili, Mao Yanyan, Gao Liubin. The emergence of new targets and new technologies, treatment prospects can be expected: 2016 review of progress in drug research and development[J]. Science and Technology Review, 2017, 35(1): 100-106.
[17] Pardoll D M. The blockade of immune checkpoints in cancer immuno- therapy[J]. Nature Reviews Cancer, 2012, 12(4): 252-264.
[18] Khalil D N, Smith E L, Brentjens R J, et al. The future of cancer treat- ment: immunomodulation, CARs and combination immunotherapy[J]. Nature Reviews Clinical Oncology, 2016, 13(5): 273.
[19] Giuroiu I, Weber J. Novel checkpoints and cosignaling molecules in cancer immunotherapy[J]. Cancer Journal, 2017, 23(1): 23.
[20] Melief C J M, Hall T V, Arens R, et al. Therapeutic cancer vaccines[J]. Dressnature Reviews Drug Discovery, 2015, 125(9): 3401.
[21] Ravaud A, Barrios C, Anak Ö, et al. Genitourinary tumors, non-pros- tate[J]. Annals of Oncology, 2012, 23(Suppl 9): ix258-ix293.